A Way for Finding Ligands for New Binding Sites

Main Article Content

K.A. Shcherbakov
A.V. Veselovsky


Analysis of protein structures shows that most of them have potential binding sites that may be considered as applicable for new ligand design. The lack of known ligands interacting with such binding sites seriously complicated potential ligands selection. We have developed an approach that can increase the effectiveness of virtual screening for such ligands. It integrates methods of de novo ligand design, pharmacophore modeling, molecular docking, molecular dynamics, calculation of binding energies by MM-GBSA. This approach starts by the de novo design of virtual library of potential compounds followed by selection of favourable substructures and their correct positioning in a new ligand binding site. This generated library has been used for a development of pharmacophore models that have been used for a virtual screening of molecular databases. The selected compounds were docked to the putative binding site to check their ability to accommodate into it and their ability to locate the identified favorable fragments in the same region of the binding site as de novo generated molecules. The further evaluation of the selected ligands can be carried out by standard CADD methods.

Article Details

How to Cite
Shcherbakov, K., & Veselovsky, A. (2023). A Way for Finding Ligands for New Binding Sites. Biomedical Chemistry: Research and Methods, 6(3), e00200. https://doi.org/10.18097/BMCRM00200


  1. Shin W.-H., Christoffer C.W., Kihara D. (2017) In silico structure-based approaches to discover protein-protein interaction-targeting drugs. Methods, 131, 22–32. DOI
  2. Kandel J., Tayara H., Chong K.T. (2021) PUResNet: prediction of protein-ligand binding sites using deep residual neural network. J. Cheminform., 13(1), 65. DOI
  3. Wang K., Zhou R., Li Y., Li M. (2021) DeepDTAF: a deep learning method to predict protein–ligand binding affinity. Brief. Bioinform., 22(5), bbab072. DOI
  4. Zhao J., Cao Y., Zhang L. (2020) Exploring the computational methods for protein-ligand binding site prediction. Comput. Struct. Biotechnol. J., 18, 417–426. DOI
  5. Roche D., Brackenridge D., McGuffin L. (2015) Proteins and their interacting partners: an introduction to protein–ligand binding site prediction methods. Int. J. Mol. Sci., 16(12), 29829–29842. DOI
  6. Veselovsky A., Archakov, A. (2007) Inhibitors of Protein-Protein Interactions as Potential Drugs. Curr. Comput.-Aided Drug Des., 3(1), 51–58. DOI
  7. Ni D., Liu Y., Kong R., Yu Z., Lu S., Zhang J. (2022) Computational elucidation of allosteric communication in proteins for allosteric drug design. Drug Discov Today, 27(8), 2226-2234. DOI
  8. Broomhead N.K., Soliman M.E. (2017) Can We Rely on Computational Predictions To Correctly Identify Ligand Binding Sites on Novel Protein Drug Targets? Assessment of Binding Site Prediction Methods and a Protocol for Validation of Predicted Binding Sites. Cell Biochem. Biophys., 75(1), 15–23. DOI
  9. Limongelli V. (2020) Ligand binding free energy and kinetics calculation in 2020. WIREs Comput. Mol. Sci., 10, e1455. DOI
  10. Sink R., Gobec S., Pecar S., Zeg, A. (2010) False Positives in the Early Stages of Drug Discovery. Curr. Med. Chem., 17(34), 4231–4255. DOI
  11. Awuni Y., Mu Y. (2015) Reduction of False Positives in Structure-Based Virtual Screening When Receptor Plasticity Is Considered. Molecules, 20(3), 5152–5164. DOI
  12. Culig Z. (2014) Targeting the androgen receptor in prostate cancer. Expert Opin. Pharmacother., 15(10), 1427-1437. DOI
  13. Thakur A., Roy A., Ghosh A., Chhabra M., Banerjee S. (2018) Abiraterone acetate in the treatment of prostate cancer. Biomed. Pharmacother., 101, 211–218. DOI
  14. Heinlein C.A., Chang C. (2004) Androgen Receptor in Prostate Cancer. Endocr. Rev., 25(2), 276–308. DOI
  15. Dagar M., Singh J.P., Dagar G., Tyagi R.K., Bagchi G. (2019) Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor. J. Biol. Chem., 294(22), 8699–8710. DOI
  16. Li J., Sun, L.; Xu C., Yu F., Zhou H., Zhao Y., Zhang J., Cai J., Mao C., Tang L., Xu Y., He J. (2012) Structure insights into mechanisms of ATP hydrolysis and the activation of human heat-shock protein 90. Acta Biochim Biophys Sin (Shanghai), 44(4), 300-306. DOI
  17. Spiegel J.O., Durrant J.D. (2020) AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization. J. Cheminform., 12(1), 25. DOI
  18. Schneidman-Duhovny D., Dror O., Inbar Y., Nussinov R., Wolfson H.J. (2008) PharmaGist: a webserver for ligand-based pharmacophore detection. Nucleic Acids Res., 36, W223–W228. DOI
  19. Koes D.R., Camacho C.J. (2012) ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res., 40, W409–W414. DOI
  20. Trott O., Olson A.J. (2009) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 31(2), 455-461. DOI
  21. Adasme M.F., Linnemann K.L., Bolz S.N., Kaiser F., Salentin S., Haupt V.J., Schroeder M. (2021) PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res., 49(W1), W530-W534. DOI
  22. Berendsen H.J.C., van der Spoel D., van Drunen R. (1995) GROMACS: A message-passing parallel molecular dynamics implementation. Comput. Phys. Commun., 91(1-3), 43-56. DOI
  23. Lindorff-Larsen K., Piana S., Palmo K., Maragakis P., Klepeis J.L., Dror R.O., Shaw D.E. (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins, 78(8), 1950-1958. DOI
  24. Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., DiNola A., Haak J.R. (1984) Molecular dynamics with coupling to an external bath. J. Chem. Phys., 81(8), 3684–3690. DOI
  25. Parrinello M., Rahman A. (1980) Crystal Structure and Pair Potentials: A Molecular-Dynamics Study. Phys. Rev. Lett., 45(14), 1196–1199. DOI